Andrew M Wollacott

This inventor holds 18 USPTO granted patents and 18 published patent applications and 4 EPO patents, primarily in Antibody Engineering. Top assignee: Visterra, Inc.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew M Wollacott. Retrieved from https://idiyas.com/inventor/andrew-m-wollacott-hzppmr5d

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 18)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Milton, MA (US) (2019 - 2024)
Waltham, MA (US) (2023 - 2024)

Company Filing History:

18 out of 38

Visterra, Inc.

patents

Years Active: 2019-2025

Loading Chart...

Areas of Expertise:

C5AR1

APRIL

Antibody Molecules

Humanized Antibodies

Drug Conjugates

Polypeptides

IgA Nephropathy

Nucleic Acid Molecules

Influenza Treatment

Therapeutic Applications

Complement 5A Receptor

Proliferation-Inducing Ligand

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12415865 - Antibody molecules to C5AR1 and uses thereof (2025-09-16),

2. 12338291 - Humanized antibody molecules to CD138 and uses thereof (2025-06-24),

3. 12264203 - Humanized complement 5a receptor 1 antibodies and methods of use thereof (2025-04-01),

4. 12227587 - Humanized complement 5A receptor 1 antibodies and methods of use thereof (2025-02-18),

5. 12187807 - Antibody molecules to C5AR1 and uses thereof (2025-01-07),

6. 12091451 - Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL) (2024-09-17),

7. 11969476 - Antibody molecule-drug conjugates and uses thereof (2024-04-30),

8. 11912781 - Humanized complement 5A receptor 1 antibodies and methods of use thereof (2024-02-27),

9. 11890319 - Antibody molecule-drug conjugates and uses thereof (2024-02-06),

10. 11858980 - Engineered polypeptides and uses thereof (2024-01-02),

11. 11773179 - Antibody molecules to C5aR1 and uses thereof (2023-10-03),

12. 11168131 - Antibody molecule-drug conjugates and uses thereof (2021-11-09),

13. 11136385 - Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule (2021-10-05),

14. 10981982 - Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL) (2021-04-20),

15. 10968270 - Antibody molecules to a proliferation-inducing ligand (APRIL) (2021-04-06),

Title: The Innovative Contributions of Andrew M Wollacott

Introduction

Andrew M Wollacott is a prominent inventor based in Milton, MA, known for his significant contributions to the field of biotechnology. With a total of 18 patents to his name, Wollacott has made remarkable advancements in the development of antibody molecules that have the potential to treat various medical disorders.

Latest Patents

Among his latest patents is the invention of antibody molecules to C5aR1, which specifically bind to the C5a receptor. These antibody molecules are disclosed for their potential use in treating, preventing, and diagnosing disorders such as ANCA-vasculitis. Another notable patent involves humanized antibody molecules to CD138, which are designed to specifically bind to CD138. These humanized antibody molecules can be utilized in the treatment, prevention, and diagnosis of disorders like multiple myeloma.

Career Highlights

Wollacott's career is marked by his role at Visterra, Inc., where he has been instrumental in advancing innovative therapeutic solutions. His work has not only contributed to the scientific community but has also paved the way for new treatment options for patients suffering from serious health conditions.

Collaborations

Wollacott has collaborated with notable colleagues, including Karthik Viswanathan and Boopathy Ramakrishnan, to further enhance the research and development of antibody therapies.

Conclusion

Andrew M Wollacott's innovative work in the field of biotechnology exemplifies the impact of dedicated inventors on medical science. His patents and collaborations continue to inspire advancements in treatment options for various disorders.

Profile summary based on public USPTO records.